
A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with aggressive disease.
“Early decline in prostate-specific antigen (PSA) to very low levels is one of the strongest predictors of long-term survival in metastatic prostate cancer. However, clinicians currently have to wait up to six months after starting therapy to see whether a patient achieves this favorable response. For patients who do not respond well, this delay may allow the cancer to progress and become more resistant to treatment,” said Soumyajit Roy, MD, a radiation oncologist at UH Seidman Cancer Center and first author of the study.
Because existin...
Read More




Recent Comments